Results: The patient was a never-smoking female and aged 43 years when she developed PAP. She had type 2 diabetes mellitus, but her occupational and exposure history was unremarkable. Screening tests for underlying HIV infection and connective tissue disease all reported negative. Examination of her peripheral blood smear did not detect leukemic cells. Her chest radiograph showed patchy and linear infiltrates mainly in the perihilar and upper fields, while her chest CT scan revealed multiple well-delineated "crazy-paving" opacities predominantly involving the apical and upper lung zones. Due to an undiagnostic bronchoalveolar lavage, peripheral wedge-biopsy of her left upper lung via video-assisted thoracoscopy was performed, and the diagnosis of PAP was established histologically. Serial pulmonary function tests showed a declining trend in her forced vital capacity, and a mild but persistent impairment in her diffusion capacity for carbon monoxide.
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Conclusion: PAP needs to be considered in the differential diagnosis for an upper-lobe predominant interstitial lung disease. Rehabilitation Center, Jichi Medical University Hospital, Japan Background and Aims: Forced vital capacity (FVC) is used for the evaluation of antifibrosis therapy; however, repeating a respiratory function test in patients with advanced idiopathic pulmonary fibrosis (IPF) is challenging. On the contrary, physical activity -a predictive indicator of prognosis in patients with IPF -is easily measurable. This study examined changes in physical activity prior to and after antifibrosis therapy in patients with IPF and their impact on the clinical course.
Methods: Physical activity was measured using a pedometer with accelerometer (Lifecorder GS; Suzuken Co. Ltd) prior to and 6 months after antifibrosis therapy. The relationship between changes in physical activity and clinical parameters (quality of life and respiratory function), number of hospitalizations, and survival were assessed.
Results: The study included 16 patients with IPF (males: 12 patients/ females: 4 patients), aged 6 AE .4 years. The background of patients prior to treatment initiation included the following: (1) treatment with nintedanib (11 patients) and pirfenidone (5 patients); (2) FVC percentage: 70. AE 6.9%; KL-6 levels: 107 AE 52 U/mL, 6-min walk distance: 39 AE 6.9 m, and steps/day: 6,42 AE ,217. Six months after initiation of therapy, Group A (8 patients) demonstrated a decrease in the rate of steps by <30%, whereas Group B (8 patients) showed a decrease by >30%. The chronic obstructive pulmonary disease assessment test and St. George's respiratory questionnaire score showed a strong tendency in Group B. Among the 7 patients (Group A: 3 patients; Group B: 4 patients) who expired during the course of treatment, the number of hospitalizations were 0.54 and 1.26 times per year in Groups A and B, respectively; survival after initiation of treatment was 22.3 and 14.3 months, respectively. process by which epithelial cells undergo a phenotypic conversion that gives rise to myofibroblasts, plays a pivotal process in the development of lung diseases such as pulmonary fibrosis. In lung diseases, alveolar epithelial cells are exposed to hypoxic condition. From recent studies that hypoxia induces EMT of alveolar epithelial cells, and histone deacetylases (HDACs) are aberrantly overexpressed in basal cells of idiopathic pulmonary fibrosis (IPF) lungs, we aimed to elucidate whether hypoxia promotes mesenchymal transition of alveolar epithelial cell through activating HDACs.
Methods:
To evaluate the effect of HDACs in alveolar EMT, we performed quantitative real-time PCR, Western blot analysis, immunocytochemistry using siRNA transfection in human and rat alveolar epithelial cells, and immunohistochemistry using a bleomycin-induced fibrosis mouse model.
Results: Hypoxia induced expression of alveolar EMT markers in A549 and RLE-6TN cells. Specifically, exposure to hypoxia decreased an epithelial marker, E-cadherin, and reversely increased expression of mesenchymal markers, Fibronectin and α-SMA in both cell lines. Additionally, a HDAC inhibitor, TSA was able to repress hypoxic effect such as loss of E-cadherin and gain of Fibronectin in alveolar epithelial cell (Fig A,B) . Among HDAC family, inhibition of HDAC3 using siRNA increased E-cadherin, and decreased Fibronectin, Snail, α-SMA in hypoxic conditions, and this process is dependent on Akt pathway. 
